Paclitaxel 150mg/25ml (AqVida)
Paclitaxel AqVida 150mg/25ml Injection is a German manufactured taxane chemotherapy agent used for breast, ovarian, and non small cell lung cancer, as well as Kaposi's sarcoma and gastric carcinoma. Buy Paclitaxel AqVida 150mg/25ml Injection at PakMeds with a valid prescription for genuine, imported stock.
Overview
A qualified oncology team administers it as an intravenous infusion after premedication to reduce allergic reactions.
Manufacturer | AqVida GmbH, Germany |
|---|---|
Active Ingredient(s) | Paclitaxel |
Strength | 150mg/25ml (6mg/ml) |
Pack Size | 1 vial |
Prescription Required | Yes |
Generic Name(s) | Paclitaxel |
Paclitaxel AqVida 150mg/25ml Injection Ingredients and Usage
Paclitaxel AqVida 150mg/25ml Injection contains paclitaxel, a taxane belonging to the antimicrotubule anticancer drug class. Oncologists prescribe it as first line therapy for ovarian carcinoma, usually combined with cisplatin, and as second line treatment after platinum based therapy fails.
Paclitaxel AqVida 150mg/25ml Injection also treats node positive breast cancer as adjuvant therapy, metastatic breast cancer in combination with trastuzumab in HER2 positive disease, non small cell lung cancer, gastric carcinoma, and AIDS related Kaposi's sarcoma. A specialist experienced in chemotherapy administration must supervise every infusion.
How Does Paclitaxel AqVida 150mg/25ml Injection Work?
Paclitaxel promotes the assembly of microtubules from tubulin dimers and stabilizes the resulting structure by preventing depolymerization. Microtubules normally disassemble and reassemble to allow cell division to proceed.
By locking microtubules in place, Paclitaxel AqVida 150mg/25ml Injection blocks the normal dynamic reorganization needed for mitosis. This arrests cancer cells during cell division and triggers cell death, slowing tumor growth across multiple cancer types.
Paclitaxel AqVida 150mg/25ml Injection Side Effects
Paclitaxel AqVida 150mg/25ml Injection commonly causes blood count changes, nerve related side effects, and injection site reactions. Close monitoring during and after infusion is standard practice.
Low white blood cell count, raising infection risk
Peripheral neuropathy, numbness or tingling in hands and feet
Hair loss
Joint and muscle pain
Nausea and vomiting
Injection site redness, swelling, or bruising
Fatigue
Warnings
Paclitaxel AqVida 150mg/25ml Injection can cause severe hypersensitivity reactions, including fatal anaphylaxis, even after standard premedication with corticosteroids, antihistamines, and an H2 blocker.
The medicine is contraindicated in patients with severe hypersensitivity to paclitaxel or to polyoxyl castor oil, an excipient in the formulation.
Avoid use in patients with a neutrophil count below 1,500 cells per cubic millimeter or a platelet count below 100,000 cells per cubic millimeter before starting a cycle.
Paclitaxel AqVida 150mg/25ml Injection is contraindicated during breastfeeding and is not recommended in pregnancy, since it can cause fetal harm.
The medicine contains dehydrated alcohol and may cause a feeling of intoxication during infusion; avoid driving or operating machinery immediately afterward.
Caution is required with medicines that inhibit or induce CYP2C8 or CYP3A4, such as ketoconazole, erythromycin, or rifampicin, since these can alter paclitaxel exposure and toxicity.
Patients should be observed continuously for at least the first 30 minutes of infusion and monitored frequently thereafter for signs of reaction.
Paclitaxel AqVida 150mg/25ml Injection Storage Conditions
Store unopened vials of Paclitaxel AqVida 150mg/25ml Injection between 20°C and 25°C, protected from light. Keep the vial in its original carton until immediately before use, and avoid exposure to direct sunlight or excess heat. Store this medicine out of reach of children and ensure only trained healthcare staff handle preparation and administration.
Customer Reviews
No reviews yet. Be the first to review this product!
Login to write a review
